David S. Boyer, MD

Clinical Professor
Department of Ophthalmology
University of Southern California/Keck School of Medicine in Los Angeles
Sr. Partner
Retina-Vitreous Associates Medical Group
1975 Zonal Ave
Los Angeles, CA 90033, USA


Dr. Boyer is a Board-Certified Ophthalmologist specializing in the treatment of diseases of the retina and vitreous. Dr. Boyer is Senior Partner at Retina-Vitreous Associates Medical Group with offices in Los Angeles, Beverly Hills, North Hollywood, Torrance, Santa Clarita, Pasadena and Tarzana, California.
Dr. Boyer is a Clinical Professor of Ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, CA.
He has an extensive research background and is currently an investigator for various clinical trials. He is one of the leading retinal clinical researchers in the country for new treatments in macular degeneration and diabetic macular edema. He serves on the Scientific Advisory Board or as a Consultant to several biotechnical or pharmaceutical companies.
A widely-published author and avid lecturer, Dr. Boyer lectures nationally and internationally on retinal research and the innovative approach to the treatment of retinal diseases. He has authored or co-authored numerous works in peer-reviewed journals, as well as served as a reviewer for ophthalmology and diabetes medical publications, including Archives of Ophthalmology, American Journal of Ophthalmology, and Ophthalmology.

Research Interest

His research interests include: Macular Degeneration and Diabetic Retinopathy.

Scientific Activities


• Physician of the Year Award,Good Samaritan Hospital, (2008)
• University of Southern California – Doheny Distinguished Alumnus Award, (2007)
• Retinitis Pigmentosa International, The Vision Awards- Jules Stein Living Tribute Award Recipient, (1996)
• American Academy of OphthalmologyBoard of Trustees Honor Award CertificateSeptember, (1995)
• Outstanding Teaching Award, University of Southern California School of Medicine, (1984-1985


• Los Angeles County Medical Association, (1977-Present)
• Los Angeles Society of Ophthalmology, (1977- Present)
• American Board of Ophthalmology Examiner, (1977-Present)
• American Academy of Ophthalmology, (1977-Present)
• California Medical Association, (1977-Present)
• California Academy of Eye Physicians and Surgeons, (1977-Present)
• American Society of Retinal Specialists, (1977-Present)
• American Medical Association, (1977-Present)
• Retina Society, (2006-Present)
• Macula Society, (2007-Present)
• American Society of Cataract & Refractive Surgery, Retina Clinical Committee Editorial Board (2007- Present)
• The Open Ophthalmology Journal – Editorial Board, (2008)


1. Federman JL, Boyer DS, Lanning R, Breit P. An Objective Analysis of Proliferative Diabetic Retinopathy Before and After Pars Plana Vitrectomy Ophthalmology. 1979; 86(2): 276-282.
2. Miller JB, Smith MR, Boyer DS. Pars plana transvitreal carbon dioxide laser photocautery: a new surgical technique J Microsurg. 1979; 1(3): 187-194
3. Miller JB, Smith MR, Boyer DS. Intraocular Carbon Dioxide Laser Photocautery Part II: Preliminary Report of Clinical Trials Arch Ophthalmol. 1979; 97(11): 2123-2127
4. Miller JB, Smith MR, Boyer DS. Intraocular Carbon Dioxide Laser Photosurgery Lasers Surg Med. 1980;1(2):165-176
5. Miller JB, Smith MR, Boyer DS. Intraocular Carbon Dioxide Laser Photocautery Ophthalmology. 1980; 87(11): 1112-1120. doi: 10.1002/lsm.1900010206
6. Goldberg RE, Boyer DS. Sequential Retinal Breaks Following a Spontaneous Initial Retinal Break. Ophthalmology. 1981; 88(1): 10-2
7. Miller JB, Smith MR, Boyer DS. Miniaturized Intraocular Carbon Dioxide Laser Photosurgical System for Multi-incision Vitrectomy Ophthalmology. 1981; 88(5): 440-442
8. Lowe MA, McDonald HR, Campo RV, Boyer DS, Schatz H. Pneumatic Retinopexy – Surgical Results Arch Ophthalmol. 1988; 106(12): 1672-1676.
9. Holland GN, Engstrom REJr, Glasgow BJ, et al. Ocular Toxoplasmosis in Patients with the Acquired Immunodeficiency Syndrome Am J Ophthalmol. 1988 Dec 15; 106(6):653-67
10. Rao NA, Zimmerman PL, Boyer D, et al. A Clinical Histopathologic and Electron Microscopic Study of Pneumocystis Carinii Choroiditis Am J Ophthalmol. 1989; 107(3):218-228
11. Dresner SC, Boyer DS, Feinfield RE. Autogenous Fascial Grafts for Exposed Retinal Buckles Arch Ophthalmol. 1991; 109(2): 288-289.
12. Hudson HL, Boyer DS, Kuppermann BD. Future Trends and Experimental Modalities in Therapeutics of Cytomegalovirus Retinitis. AIDS and Ophthalmology: New Solutions. Ophthalmology Clinics of North America. 1997; 10(1): 61-71.
13. Kim J, McDonald HR, Rubsamen PE, et al. Surfing-Related Ocular Injuries, Retina. 1998; 18(5): 424-429
14. Gallemore RP, Boyer DS. Retinal Detachment: The Best Treatment is Prevention Review of Ophthalmol. 2001.
15. Gallemore, RP, Boyer, DS. Save Your Sight. Eye Disease and HIV. Positive Living 2001-2002; 10(7):2 9-30
16. Gallemore RP, Boyer DS. Buckle, Vitrectomy or Bubble: RD Management Options. Review of Ophthalmology. 2002; 9(4).
17. Hamdi HK, Reznik J, Castellon R, et al. Alu DNA Polymorphism in ACE Gene is Protective for Age-related Macular Degeneration Biochem Biophys Res Commun. 2002; 295(3): 668-672
18. Navas F, Boyer DS, Thomas EL, Novack RL, Chu TG, Gallemore RP. Management of Pupillary Block Glaucoma in Phakic Patients after Vitrectomy with Silicone Oil Injection Am J Ophthalmol. 2002; 134(4): 634-635.
19. Gallemore RP, Thomas EL, Boyer DS. Minimally Invasive Vitreoretinal Surgery Review of Ophthalmol. 9:11, Issue 11/19/02
20. Ng EW, Bressler NM, Boyer DS, de Juan E. Jr Iatrogenic Choroidal Neovascularization Occurring in Patients Undergoing Macular Surgery Retina. 2002 Dec;22(6):711-8
21. Gallemore RP, Boyer DS. AMD Treatment Update: Along with Visudyne and TTT, Injectable Anti-angiogenesis Agents are on the Forefront of Current Research Ophthalmology Management. March 2003
22. Boyer DS, Gallemore RP. Clinical Trials Assess Rheopheresis Review of Ophthalmol. 2003; 10(8).
23. Taban M, Boyer DS, Thomas EL, Taban M. Chronic Central Serous Chorioretinopathy: Photodynamic Therapy, Am J Ophthalmol. 2004; 137(6): 1073-1080. doi: 10.1016/j.ajo.2004.01.043
24. Taban M, Thomas EL, Boyer DS, Novack RL, Chu TG, Gallemore RP. Efficiency of Verteporfin Photodynamic Therapy on Laser-Induced Choroidal Neovascularization and the Ancillary Effect on Diabetic Microvasculopathy Curr Eye Research. 2004; 28(4): 291-295.
25. Gallemore RP, Boyer DS, Thomas EL. Evolving Treatment Strategies for Diabetic Retinopathy Retina Physician. 2004; 1(2): 24-27.
26. Visudyne in Minimally Classic Choroidal Neovascularization Study Group: Verteporfin Therapy of Subfoveal Minimally Classic Choroidal Neovascularization Related Macular Degeneration: 2-year Results of a Randomized Clinical Trial Arch Ophthalmol. 2005; 123(4): 448-57
27. Kappel PJ, Charonis AC, Holland GN, et al. Southern California HIV/Eye Consortium. Outcomes associated with ganciclovir implants in patients with AIDS-related cytomegalovirus retinitis Ophthalmology. 2006; 113(4): 683.
28. MARINA Study Group. Ranibizumab for Neovascular Age-Related Macular Degeneration: 1-Year Results of the MARINA Study New England Journal of Medicine. N Eng J Med. 2006; 355:1419-1431. doi: 10.1016/j.ophtha.2008.10.018
29. FOCUS Study Group Ranibizumab combined with Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration (FOCUS): Year 1 Results Arch of Ophthalmology. 2006; 124(11): 1532-1542
30. Kappel PJ, Charonis AC, Holland GN, et al. for the Southern California HIV/Consortium. Outcomes Associated with Ganciclovir Implants in Patients with AIDS-Related Cytomegalovirus Retinitis Ophthalmology. 2006; 113(4): e1-e8.
31. Pulido, JS, Winters, JL, Boyer, DS. Preliminary Analysis of the final Multicenter Investigation of Rheopheresis for Age related Macular Degeneration (AMD) Trial (MIRA-1) Results Trans Am Ophthalmol 2006; 104: 221-231.
32. MARINA Study Group Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular. Age-Related macular Degeneration Ophthalmology. 114(2): 2007
33. Boyer DS, Gallemore RP. Changing Approaches to Diabetic Retinopathy Review of Ophthalmology 2007; 88-92.
34. Aiello LM, Rajiv A, Blumenkrantz M, et al. Effect of Ruboxistaurin in patients with Diabetic Macular Edema: Thirty-Month Results of the Randomized PKC-DMES Clinical Trial Arch Ophthalmol. 2007; 125: 318-324.
35. Narayanan R, Butani V, Boyer DS, et al. Complement Factor H Polymorphism in Age-Related Macular Degeneration Ophthalmology. 2007; 114: 1327-1331
36. ADD-V Study Group: Effect of Adjunctive Diclofenac with Verteporfin Therapy to treat Choroidal Neovascularization due to Age-Related Macular Degeneration Phase II Study Retina. 2007; 27(6): 693-700
37. VALIO Study Group Verteporfin Therapy of Subfoveal Occult CNV in AMD Using Delayed Light Application: One-Year Results of the VALIO Study American Journal of Ophth. 2007; 144(6): 970-972
38. ANCHOR Study Group: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular Degeneration: Two year results of the ANCHOR Study, Ophthalmology. 2009; 116(1): 57-65
39. Udar N, Atilano SR, Memarzadeh M, et al. Mitochondrial DNA haplogroups associated with Age-related Macular Degeneration Invest Ophthalmol Vis Sci. 2009;50(6):2966-74. doi: 10.1167/iovs.08-2646
40. Hnik P, Boyer DS, Grillone LR, Clement JG, Henry SP, Green EA. Antisense Oligonucleotide Therapy in Diabetic Retinopathy. The Journal of Diabetes Science and Technology 2009; 3(4).
41. Kaiser PK. Visudyne in Occult CNV (VIO) study group. Verteporfin PDT for subfoveal Occult CNV in AMD; two-year results of a randomized trial Curr Med Res Opin. , 2009 Augl 25(8): 1853-1860. doi: 10.1185/03007990903038616
42. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-Related Macular Degeneration Ophthalmology 2009; 116(9): 1731-1739. doi: 10.1016/j.ophtha.2009.05.024
43. READ-2 Study Group Primary End Point (Six Months) Results of the Ranibizumab for Edema of the Macula in diabetes (READ-2)study Ophthalmology 2009; 116(11): 2175-2181.
44. Kenney MC, Atilano SR, Boyer D, et al. Characterization of Retinal and Blood Mitochondrial DNA from Age-related macular Degeneration Patients Invest Ophthalmol Vis Sci 2010. doi: 10.1167/iovs.09-4778
45. Roe RH, Boyer DS, Spirn MJ, Bakri SJ. Diagnostic and therapeutic challenges Retina. 2010; 30(7): 1155-8. doi: 10.1097/IAE.0b013e31820f4825
46. Saddas S, Stoller G, Boyer D, Blodi B, Shapiro H, Ianchulev T. Anatomical Benefit from Ranibizumab Treatment of Predominantly Classic Neovascular Age-Related Macular Degeneration in the 2-Year ANCHOR Study Retina. 2010; 30: 1390-1399. doi: 10.1097/IAE.0b013e3181e44599
47. Uddin PQ, Boyer D, Siegel RJ. Retinal Artery Embolization from a Calcified Bicuspid Aortic Valve Causing Amaurosis Fugax The American Journal of Medicine. 2010; 123(12): 1091-1093. doi: 10.1016/j.amjmed.2010.06.024
48. Ozurdex CHAMPLAIN Study group: Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectimized patients Retina. 2011 May;315(5):915-23. doi: 10.1097/IAE.0b013e318206d18c
49. Tabandeh H, Chaudhury NA, Boyer DS, Kon-Jara VA, Flynn HW Jr. Outcomes of cataract surgery in patients with neovascular age-related maculat degeneration in the era of anti-vascular endothelial growth factor therapy J Cataract Refrac Surg. 2012; 38(4): 677-682. doi: 10.1016/j.jcrs.2011.10.036
50. RIDE Research Group: Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE Ophthalmology. 2012; 119(4): 789-801. doi: 10.1016/j.ophtha.2011.12.039
51. DENALI Study Group: Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration: Twelve-Month Results of the DENALI Study Ophthalmology. 2012; 119(5): 1001-1010. doi: 10.1016/j.ophtha.2012.02.003
52. FAME Study Group: Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema Ophthalmology. 2012. doi: 10.1016/j.ophtha.2012.04.030
53. Bressler NM, Boyer DS, Williams DF, et al. Verebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials Retina. 2012; 32(9): 1821-1828. doi: 10.1097/IAE.0b013e31825db6ba
54. Carle MV, Boyer DS, Dayani P. Punctate inner choroidopathy and Optic Neuropathy: a simultaneous presentation in a patient – a case report Journal of Ocular Inflammation and Immunology. 2013; 3(54). doi: 10.1186/1869-5760-3-54
55. Kenney MC, Hertzog D, Chak G, et al. Mitochondrial DNA haplogroups confer differences in risk for age-related macular degeneration a case control study BMC Med Genet. 2013; 14: 4. doi: 10.1186/1471-2350-14-4
56. Kenney MC, Chwa M, Atilano SR, et al. Udar N Mitochondrial DNA variants meditate energy production and expression levels for CFH, C3 and EFEMP1 genes: implications for age-related macular degeneration PLos One. 2013; 8(1): e54339. doi: 10.1371/journal.pone.0054339.
57. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study AM J Ophthalmol. 2013; 155(3): 429-437. doi: 10.1016/j.ajo.2012.09.026
58. Carle MV, Boyer DS, Dayani PN. Punctate inner choroidopathy and optice neuropathy: Simultaneous presentation in a patient – a case report J Ophthalmic Inflamm Infect. 2013; 3(1): 54. doi: 10.1186/1869-5760-3-54
59. Carle MV, Chu TG, Tabandeh H, Boyer DS. Intravitreal aflibercept use in the treatment of macular edema from central retinal vein occlusion: Expert Review of Ophthalmology 2013; 8(3): 27-235. doi: 10.1586.eop.13.21
60. John VJ, Flynn HW Jr, Smiddy WE, et al. Clinical course of vitreomacular adhesion managed by initial observation Retina. 2013. doi: 10.1097/IAE.0b013e3182a15f8b
61. Ozurdex PLACID Study Group: Dexamethasone intravitreal impant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013 Sep;120(9):1843-51. doi: 10.1016/j.ophth.2013.02.018
62. RISE Research Group Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE Ophthalmology. 2013; 120(10): 2013-2022. doi: 10.1016/j.ophtha.2013.02.034
J Glaucoma. 2013; 14. doi: 10.1097/IJG.000000000000002
64. SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a Multicenter cohort study (SEVEN-UP) Ophthalmology. 2013; 120(11): 2292-2299. doi: 10.1016/j.ophtha.2013.03.046
65. Kenney MC, Chwa M, Atilano SR, et al. Molecular and bioenergetic differences between cells with African versus European inherited mitochondrial DNA haplogroups: Implications for population susceptibility to diseases Biochem Biophys Acta. 2014; 1842(2): 208-219. doi: 10.1016/j.bbadis.2013.10.016
66. Carle MV, Boyer DS, Liao D, Chu T. Successful use of anti-VEGF treatment for subretinal hemorrhage and fluid in a young patient with Chroidal Osteoma Ophthalmic Surg Lasers Imaging Retina. 2014; 45(2): XXX-X. doi: 10.3928/23258160-20140306-12.
67. Kenney CM, Chwa M, Atilano SR, et al. Inherited mitochondrial DNA variants can affect complement, inflammation and apoptosis pathways: insights into mitochondrial-nuclear interactions. Hum Mol Genet. 2014; 23(13): 3537-3551. doi: 10.1093/hmg/ddu065
68. Carle MV, Chu TG, Liao D, Boyer DS. Successful use of anti-VEGF treatment for subretinal hemorrhage and fluid in a young patient with choroidal osteoma Ophthalmic Surg Lasers Imaging Retina. 2014; 45(2): 169-171. doi: 10.3928/23258160-20140306-12
69. Carle MV, Roe R, Novack R, Boyer DS. Cosmetic facial fillers and severe vision loss JAMA Ophthalmol. 2014; 132(5): 637-639.
70. Malik D, Hsu T, Falatoonzadeh P, et al. Human retinal transmitochondrial cybrids with J or H mtDNA haplogroups respond differently to ultraviolet radiation: implications for retinal diseases. PLoS One . 2014; 9(2): e99003. doi: 10.1371/journal.pone.0099003
71. Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema Ophthalmology. 2014; 121(10): 1904-1914. doi: 10.1016/j.ophtha.2014.04.024
72. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: The 24-Week Results of the VIBRANT Study Ophthalmology. 2014. doi:. doi: 10.1016/j.ophtha.2014.08.031
73. Bakri SJ, Boyer DS, Albini TA, et al. Comparison of the tissue penetration and glide force of 22-gauge thin-wall needles for intravitreal implant administration Ophthalmic Surg Lasers Imaging Retina. 2014; 45(5): 430-435.
74. Korobelnik JF, Do DV, Erfurth SU, et al. Intravitreal aflibercept for diabetic macular edema Ophthalmology. 2014; 121(11): 2247-2254. doi: 10.1016/j.ophtha.2014.05.006.
75. V.I.S.I.O.N. Study Group. Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study Br J Ophthalmol. 2014; 98(11): 1543-1546. doi: 10.1136/bjophthalmol-2013-304075
76. Campochiaro PA, Sophie R, Tolentino M, et al. Treatment of Diabetic Macular Edema with an Inhibitor of Vascular Endothelial-Protein Tyrosine Phosphatase That Activates Tie2 Ophthalmology. 2014; 12. doi: 10.1016/j.ophtha.2014.09.023
77. Carle MV, Boyer DS. A new choroidal mass in a patient with known metastatic leiomyosarcoma: importance of fine-needle aspirate biopsy in diagnostic certainty and treatment planning. Retin Cases Brief Rep. 2014; 8(4): 292-294.. doi: 10.1097/ICB.0000000000000056
78. Campochiaro PA, Sophie R, Tolentino M, et al. Treatment of Diabetic Macular Edema with an Inhibitor of Vascular Endothelial-Protein Tyrosine Phosphatase That Activates Tie2 Ophthalmology. 2015; 122(3):545-54. doi: 10.1016/j.ophtha.2014.09.023
79. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: The 24-Week Results of the VIBRANT Study Ophthalmology. 2015; 122(3): 538-544. doi: 10.1016/j.ophtha.2014.08.031.
80. Gonzalez VS, Boyer DS, Schmidt-Erfurth U, et al. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept Retina. 2015; 35(4): 687-694. doi: 10.1097/IAE.0000000000000430.
81. Bhisitkul RB, Mendes TS, Rofagha S, Enanoria W, Boyer DS, Sadda SR, Zhang K. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. AmJ Ophthalmol. 2015; 159(5): 915-924.e2. doi: doi: 10.1016/j.ajo.2015.01.032
82. Tzu JH, John VJ, Flynn HW Jr, et al. Clinical Course of Vitreomacular Traction Managed Initially by Observation. Ophthalmic Surg Lasers Imaging Retina. 2015; 46(5): 571-576. doi: 10.3928/23258160-20150521-09. doi: 10.3928/23258160-20150521-09.
83. Rahimy E, Reddy S, DeCroos FC, et al. Prospective evaluation of visual acuity agreement between standard early treatment diabetic retinopathy study chart and a handheld equivalent in eyes with retinal pathology Retina. 2015;35(8):1680-7. doi: 10.1097/IAE.0000000000000518.
84. Atilano SR, Malik D, Chwa M, et al. Mitochondrial DNA variants can mediate methylation status of inflammation, angiogenesis and signaling genes Hum Mol Genet. 2015; 24(16): 4491-503. doi: 10.1093/hmg/ddv173
85. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology. 2015; 122(10): 2044-2052. doi: 10.1016/j.ophtha.2015.06.017